Long‐term hepatic function of patients with compensated cirrhosis following successful direct‐acting antiviral treatment for hepatitis C virus infection
| Autor: | Nobuyuki Yamashita, Aritsune Ooho, Shinji Shimoda, Hideyuki Nomura, Chie Morita, Jun Hayashi, Yasunori Ichiki, Eiji Kajiwara, Eiichi Ogawa, Koichi Azuma, Toshimasa Koyanagi, Takeaki Satoh, Makoto Nakamuta, Kimihiko Yanagita, Naoki Yamashita, Masami Kuniyoshi, Kazuhiro Takahashi, Akira Kawano, Kazufumi Dohmen, Norihiro Furusyo, Masaki Kato, Rie Sugimoto |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Liver Cirrhosis
Male medicine.medical_specialty Cirrhosis Hepatitis C virus medicine.disease_cause Antiviral Agents Gastroenterology Cohort Studies Hepatic function Internal medicine medicine Humans Decompensation Stage (cooking) Aged Hepatology business.industry medicine.disease Hepatitis C Confidence interval Treatment Outcome Cohort Female business Cohort study |
| Zdroj: | Journal of Gastroenterology and Hepatology. 37:371-377 |
| ISSN: | 1440-1746 0815-9319 |
| Popis: | BACKGROUND AND AIM Direct-acting antivirals (DAAs) have contributed to the improvement of outcomes for all patients with chronic hepatitis C. The aim of this study was to evaluate the long-term hepatic benefits of hepatitis C virus (HCV) cure by DAAs in patients with compensated cirrhosis. METHODS This multicenter cohort study consisted of consecutive patients with compensated cirrhosis who initiated interferon-free DAA treatment before September 2016. The impact of treatment on long-term hepatic function was followed for at least 4 years after the end of treatment, and the progression to decompensation was evaluated. RESULTS The data of 394 patients were available for study. The median age was 70, and 41% had modified albumin-bilirubin (ALBI) grade 2b. During a short-term follow-up 1 year after the end of treatment, FIB-4 index and ALBI score significantly improved. The achievement rates of FIB-4 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text